Myosana Platform for XLMTM

About Myosana Therapeutics

Myosana Therapeutics is an early-stage, privately held biotech focused on creating a transformative, non-viral gene delivery platform for genetic muscle diseases. The company has secured seed funding and strategic investments from patient advocacy groups to advance its lead programs. Its core strategy is to develop a targeted, muscle-specific delivery system that could expand the treatable disease landscape beyond the constraints of viral-based therapies.

Therapeutic Areas